



## Antimalarial sesquiterpene lactones from *Distephanus angulifolius*

Martin M. Pedersen<sup>a</sup>, Jude C. Chukwujekwu<sup>b</sup>, Carmen A. Lategan<sup>c</sup>, Johannes van Staden<sup>b</sup>, Peter J. Smith<sup>c</sup>, Dan Staerk<sup>d,\*</sup>

<sup>a</sup> Department of Medicinal Chemistry, Faculty of Pharmaceutical Sciences, University of Copenhagen, Universitetsparken 2, DK-2100 Copenhagen, Denmark

<sup>b</sup> Research Centre for Plant Growth and Development, School of Biological and Conservation Science, University of KwaZulu-Natal Pietermaritzburg, Private Bag X01, Scottsville 3209, South Africa

<sup>c</sup> Department of Medicine, Division of Pharmacology, University of Cape Town, Observatory 7925, Capetown, South Africa

<sup>d</sup> Department of Basic Sciences and Environment, Faculty of Life Sciences, University of Copenhagen, Thorvaldsensvej 40, DK-1871 Frederiksberg, Denmark

### ARTICLE INFO

#### Article history:

Received 18 December 2008

Received in revised form 29 January 2009

Available online 18 March 2009

#### Keywords:

*Distephanus angulifolius*

*Vernonia angulifolia*

Asteraceae

Sesquiterpene lactones

Elemanolide

Heliangolide

Antiplasmodial activity

### ABSTRACT

Combined use of bioassay-guided fractionation based on *in vitro* antiplasmodial assay and dereplication based on HPLC–PDA–MS–SPE–NMR led to isolation of (6S,7R,8S)-14-acetoxy-8-[2-hydroxymethylacrylat]-15-helianga-1(10),4,11(13)-trien-15-al-6,12-olid and (5R,6R,7R,8S,10S)-14-acetoxy-8-[2-hydroxymethylacrylat]-elema-1,3,11(13)-trien-15-al-6,12-olid, along with vernodalol, vernodalin, and 11,13β-dihydroxyvernodalol from extract of *Distephanus angulifolius*. All compounds were identified by spectroscopic methods, including 1D and 2D homo- and heteronuclear NMR experiments. The isolated compounds showed IC<sub>50</sub> values in the range 1.6–3.8 μM and 2.1–4.9 μM against chloroquine sensitive D10 and chloroquine resistant W2 *Plasmodium falciparum* strains, respectively.

© 2009 Elsevier Ltd. All rights reserved.

### 1. Introduction


Drug discovery based on results from *in vitro* antiplasmodial bioassays, i.e., bioassay-guided isolation, has revealed many active constituents from complex mixtures of biological origin, e.g., plant extracts, marine organisms, and microorganisms. However, the method suffers from several problems, including limited compatibility with high-throughput technologies typically used in pharmaceutical drug discovery programmes (Butler, 2004), results from *in vitro* assays do not necessarily reflect *in vivo* activity (Bourdy et al., 2008), need for time-consuming preparative-scale isolation for *in vitro* bioassays, and the risk of spending time on isolation of known compounds with known activity. Urgent need for new antimalarial drug candidates calls for alleviation of some of these drawbacks, and the latter can be partly solved by applying chemical screening technologies that identifies the extract-constituents before or simultaneous with the bioassay-guided fractionation. Although LC–MS is a fast and sensitive technique that is frequently used for chemical screening, mass spectrometry lacks the possibility of rigorous structure elucidation that is provided by NMR spectroscopy. In a series of recent papers, it has been demonstrated that hyphenated HPLC–SPE–NMR is a fast, sensitive and

efficient technique for analytical-scale identification of constituents in complex mixtures (Clarkson et al., 2006a; Schmidt et al., 2008; Sprogø et al., 2007; Sørensen et al., 2007; Tatsis et al., 2007), including full structure elucidation of even very complex structures (Clarkson et al., 2006b) and assignment of absolute stereochemistry by combining the technique with circular dichroism (Sprogø et al., 2008). The HPLC–SPE–NMR technique has been extended to include direct on-line identification of radical scavenging activity (Pukalskas et al., 2005), but the simultaneous identification of chemical structure and biological activity is not possible in most cases. In this work, the two complementary strategies, i.e., chemical screening based on HPLC–PDA–MS–SPE–NMR and biological screening based on results from *in vitro* antiplasmodial assays, were performed simultaneous on an extract of *Distephanus angulifolius* (DC.) H. Rob. & B. Kahn [syn. *Vernonia angulifolia* DC.] (Robinson and Kahn, 1986) to avoid preparative-scale isolation of uninteresting constituents, both in terms of chemical structure and biological activity.

*Distephanus* and *Vernonia* are closely related genera within the Asteraceae (Robinson, 2006), but whereas phytochemical information on *Distephanus* is scarce (Jakupovic et al., 1987), *Vernonia* is known to be a rich source of sesquiterpene lactones. *Vernonia amygdalina* is probably one of the most intensively investigated *Vernonia* species due to reports of its use as an antiparasitic remedy by wild chimpanzees (Huffman and Seifu, 1989; Jisaka et al., 1992;

\* Corresponding author. Tel.: +45 35332425; fax: +45 35332398.

E-mail address: [dst@life.ku.dk](mailto:dst@life.ku.dk) (D. Staerk).



**Fig. 1.** HPLC-PDA-MS-SPE-NMR analysis of defatted extract of *V. angulifolia* aerial parts using UV-trace at 220 nm (grey) or 254 nm (black) for threshold-based adsorption on SPE cartridges. Constituents were identified as chlorogenic acid analogs (peak 1–3), vernodalol (peak 4), vernodalol (peak 5), 11,13-dihydrovernodalol (peak 6), **1** (peak 7), **2** (peak 9) and several unidentified steroid saponins (peak 8, 10–17) [Phenomenex Luna C<sub>18</sub>(2) column, 150 × 4.6 mm i.d., 3 μm, flow rate 0.8 ml/min, acetonitrile gradient in water (0.1% formic acid) as shown].

Koshimizu et al., 1994; Ohigashi et al., 1994) but other activities, including antitumoral (Jisaka et al., 1993), antibacterial (Erasto et al., 2006; Rabe et al., 2002; Reid et al., 2001), antioxidant (Erasto et al., 2007), anti-inflammatory (Cioffi et al., 2004), insect antifeedant (Ganjian et al., 1983), and cytotoxicity (Koul et al., 2003), have been reported from various *Vernonia* species.

*Distephanus angulifolius* is a scrambling shrub or climber which in South Africa is found from the Eastern Cape to Mozambique. It is commonly known as “Trailing Vernonia” due to its growth habit, and in Zulu, it is called impoqompqwane. According to Pooley (1998), *D. angulifolius* is used traditionally to treat stomach ailments, and an earlier investigation reported the presence of four germacranolide-type sesquiterpene lactones (Bohlmann et al., 1978). In this work, aerial parts were investigated for constituents responsible for the antiplasmodial constituents.

## 2. Results and discussion

HPLC–PDA–MS–SPE–NMR was used for initial analysis of a defatted dichloromethane-methanol extract (extract A) of *D. angulifolius*. A total of 17 peaks were analyzed (Fig. 1), showing the presence of chlorogenic acid analogs (peak 1–3), vernodalol (peak 4, 3), vernodalol (peak 5, 4), 11,13-dihydrovernodalol (peak 6, 5), compound **1** (peak 7), compound **2** (peak 9), and several steroid saponins (peak 8 and 10–17). Structural formulae of all isolated sesquiterpene lactones are shown in Fig. 2. In a concurrent study, bioassay-guided isolation of an acetone extract revealed two fractions giving less than 10% survival of chloroquine sensitive *P. falciparum* parasites *in vitro*, and <sup>1</sup>H NMR spectral data indicated the presence of sesquiterpene lactones. Based on these results, preparative-scale HPLC of the defatted extract was performed aiming at isolation of the sesquiterpene lactones. This afforded **3** and a fraction, which after being rechromatographed using analytical-scale HPLC with automated fraction collection, yielded **4**, **5**, and a mixture of **6** and **7** (2:1). Due to the limited amount, **6** and **7** were not further purified but their identity established within the mixture.

Further bioassay-guided fractionation of the two fractions of the acetone extract by column chromatography and preparative-scale TLC yielded **1**, **2**, **3**, and a mixture of **4** and **5** as the active principles.

Compound **1** was assigned the molecular formula C<sub>21</sub>H<sub>24</sub>O<sub>8</sub> as determined by HRMS (*m/z* 427.1369 [M+Na]<sup>+</sup>). The structure was established by correlations found in 2D COSY, NOESY, HSQC and

HMBC spectra, and full assignment of all correlations are given in Supplementary Table 1. Thus, the H-1→H-2→H-3 and the H-5→H-6→H-7→H-8→H-9 spin systems were identified by the COSY experiments and these fragments were, together with C-4 and C-10, combined by correlations observed in the HMBC spectrum (Fig. 3), to form the 10-membered cyclic carbon skeleton. Similarly, HMBC were used for showing the position of the aldehyde, the 2-(hydroxymethyl)acrylate, and the acetyl groups at C-4, C-8, and C-14, respectively. The relative configuration of **1** was established by analysis of <sup>1</sup>H coupling patterns and the NOESY spectrum. Thus, using H-7 as anchoring point, strong NOESY cross peaks to H-1, H-5 and H-9α showed their position below the plane of the ring (Fig. 3). Similarly, NOESY correlations between H-1, H-5 and H-15 confirmed their α-position and thus the *E*-configuration of the C4–C5 double bond. The *E*-configuration was further confirmed by the down-field position (δ 6.54) of H-5 and the up-field position (δ 9.52) of H-15 (Fortuna et al., 2001) as compared to related compounds with *Z*-configuration (δ<sub>H-5</sub> ~ 6.11, δ<sub>H-15</sub> ~ 10.2, respectively) (Seaman and Fischer, 1980). The 1,2-trans-diaxial relation between H-7 and H-8 was evident from their large coupling constant (<sup>3</sup>*J*<sub>H7–H8</sub> = 9.8 Hz) which leads to the β-pseudoaxial position of H-8 and consequently the α-pseudoequatorial position of the 2-(hydroxymethyl)acrylate group. Based on the β-position of H-8, the NOESY correlation network illustrated on the right-hand side of Fig. 3 confirms the position of H-3β, H-6, H-9β and the acetyl group above the plane, and thus the *Z*-configuration of the C1–C10 double bond. These observations and comparison of the negative optical rotation ([α]<sub>D</sub><sup>20</sup> = −9.2) of **1** with the optical rotation of a related structure with 6*R*,7*R*,8*S* configuration (Roselli et al., 2003), leads to the 1(10)-*Z*,4-*E*,6*R*,7*R*,8*S* configuration of **1**. Compound **1** is a new compound for which the name vernangulide **1** is proposed. A related structure with an acetyl instead of a 2-(hydroxymethyl)acrylate at C-8 has previously been isolated from *Mikania minima* (Asteraceae) (Cuenca et al., 1993).

Compound **2** was assigned the molecular formula C<sub>21</sub>H<sub>24</sub>O<sub>8</sub> based on HRMS (*m/z* 427.1442 [M+Na]<sup>+</sup>), and analysis of 2D COSY, NOESY, HSQC and HMBC experiments (see Supplementary Table 2) established the structure of this elemanolide analogue. Thus, the axial position of H-5, H-6, H-7 and H-8 of the pseudo-chair-formed cyclohexane was evident from the coupling constants (<sup>3</sup>*J*<sub>H-5,H-6</sub> = 12.3, <sup>3</sup>*J*<sub>H-6,H-7</sub> = 11.3, <sup>3</sup>*J*<sub>H-7,H-8</sub> = 11.0). This led consequently to the equatorial position of the 3-oxopropen-2-yl and 2-(hydroxymethyl)acrylate groups, which were identified as substituents at C-5 and C-8, respectively, by HMBC correlations. The chair form of the cyclohexane moiety was further supported by strong NOESY cross peaks between H-6 and H-8, and between H-5, H-7 and H-9α, due to their 1,3-diaxial position. The vinyl group at C-10 was positioned equatorial (α-position) based on NOESY correlations from H-1 and H-2 to H-5, H-7 and H-9α, thus leading to axial position (β-position) of the acetoxymethyl group. This axial position is in agreement with NOESY correlations observed between H-14A and H-9 eq, and between H-14B and H-6, H-8, and H-3B. The different NOE correlations observed for H-14A and H-14B is in agreement with the preferred conformation of **2** obtained by molecular modeling. Thus, the preferred orientation of the 3-oxopropen-2-yl, the vinyl and the acetoxymethyl groups were assessed by continuously calculating minimized molecular energy levels when employing a dihedral driver schedule with a resolution of 1° for the C3–C4–C5–C10, C2–C1–C10–C5 and C9–C10–C14–O14 dihedral angles, respectively. The obtained model (Fig. 4) shows that the cyclohexane moiety of **2** adopts a pseudo-chair conformation with orientation of the side chains that correlates with the observed NOESY correlations. Previous work (Karamenderes et al., 2007) with a related structure (**8**) concludes, based on the observation of a small, rather than a strong, ROESY cross peak between H-14a and H-6, that **8** adopts a boat conformation. This conclusion is




Fig. 2. Structure of compounds 1–8.


contrary to their own analysis of coupling constants and a molecular modeling study, which both suggest a chair conformation. In addition, there is no further evidence for the boat-conformation, e.g., information about a strong ROE between H-6 and H-9b, or other ROE's supporting the boat conformation. In this study, both coupling constants, observed NOE's and molecular modeling studies suggests that the cyclohexane part of **2** adopts a pseudo-chair conformation. The absolute configuration of **2** is 5*R*,6*R*,7*R*,8*S*,10*R* based on comparison of the optical rotation ( $[\alpha]_D^{20} = +26.3$ ) with data from related structures possessing the same chiral skeleton with achiral substituents (Roselli et al., 2003; Karamenderes et al., 2007; Cardona et al., 1997). Compound **2** is a new compound for which the name vernangulide B is suggested.

Compounds **3**–**5** were identified as vernodalol, vernodalin and 11,13β-dihydrovernodalol, respectively, based on comparison of


spectroscopic data (optical rotation, <sup>1</sup>H and <sup>13</sup>C NMR; see Supplementary Tables 3–5) with data from literature (Erasto et al., 2007; Abegaz et al., 1994; Reid et al., 2001; Al Magboul et al., 1997) as well as by full assignment of 1D and 2D NMR spectroscopic data.

Compounds **6** and **7** were isolated as a mixture and identified as the C6,C12-ring-opened forms of vernodalin and 11,13β-dihydrovernodalol. Lactones exist in equilibrium with their ring-opened analogs, and consequently **6** and **7** should not be considered as independent compounds. However, because **6** and **7** could be isolated as the ring-opened form without their lactonized analogs, <sup>1</sup>H NMR data are given for future reference (Supplementary Tables 6 and 7).

Antiplasmodial activity of **1**–**4** against chloroquine sensitive D10 and chloroquine resistant W2 *P. falciparum* strains are shown



**Fig. 3.** Selected correlations from 2D COSY, HMBC and NOESY experiments. Left: Spin systems found by COSY shown with bold lines; HMBC correlations (H → C) used for establishment of skeleton. Middle: NOE correlations for hydrogens positioned below plane of ring system. Right: NOE correlations for hydrogens positioned above plane of ring system [ $^1\text{H}$  resonance frequency 400 MHz; acetone- $d_6$ ; double-quantum filtered COSY; phase-sensitive NOESY, mixingtime of 600 ms; gradient-selected HMBC,  $^nJ_{\text{CH}} = 7.7 \text{ Hz}$ ].



**Fig. 4.** Model of preferred conformation of **2** [ChemBio3D Ultra, dihedral driver (resolution  $1^\circ$ ) with calculated energy minima (MM2) for each step].

in Table 2. All tested compounds have  $\text{IC}_{50}$  values in the low  $\mu\text{M}$  range against both D10 and W2 strains. Compounds **1** and **2** show slightly better effect than **3**, with **2** having the lowest resistance index. Compounds **2** and **3** show a selectivity index 2.8 and 3.6 times higher, respectively, than **1**.

### 3. Conclusion

In this work, fast dereplication of extract constituents avoided time-consuming preparative-scale isolation of steroid saponins, which due to their amphiphilic and/or detergent properties are likely to give false-positive response in *in vitro* antiparasitodal assays due to membrane alterations (Ziegler et al., 2002, 2004; Sairafianpour et al., 2003). In addition, results from bioassay-guided fractionation targeted preparative-scale isolation towards the sesquiterpene lactones. It is well-established that sesquiterpene lactones possess a general cytotoxicity mediated by their  $\alpha,\beta$ -unsaturated carbonyls (Scotti et al., 2007; Zhang et al., 2005). These structural elements react with cysteine sulfhydryl groups by a Michael type addition, thus making covalent adducts with cysteine residues of the proteins. However, **2** and **3** showed both low resistance index and high selectivity index, which make them interesting as chemotherapeutic lead structures against

chloroquine resistant *P. falciparum*. Future improvements in antimalarial chemotherapy based on sesquiterpene lactones could originate from medicinal chemistry studies aiming at synthesis of analogs with increased selectivity and lowered resistance index, and further understanding of drug-delivery mechanisms, including parasite transporter-based strategies (Biagini et al., 2005), opens new horizons for targeting the increased mortality due to drug-resistant malaria.

## 4. Experimental

### 4.1. General

Optical rotations were recorded using a Perkin-Elmer 241 polarimeter. NMR spectra of isolated compounds were recorded at  $25^\circ\text{C}$  using a Bruker Avance 600 MHz equipped with a 5 mm  $^1\text{H}\{^{13}\text{C}\}$  probe or a Bruker Avance 400 MHz spectrometer equipped with a 5 mm  $^{13}\text{C}\{^1\text{H}\}$  probe ( $^1\text{H}$  resonance frequency 600.13 and 400.13 MHz, respectively). Spectra were calibrated using TMS as internal standard. High-resolution mass determinations were carried out using a Micromass LCT mass spectrometer equipped with an electro-spray ion source operated in positive-ion mode. The spectra were calibrated relative to Leu-Enkephalin (556.2771 g/mol) added as an internal standard. Preparative-scale separations were performed using an Agilent 1100 LC system (two preparative pumps, an autosampler, a sample collector, and a multiple-wavelength UV detector; controlled with ChemStation rev. B.01.01 software; HPLC system I), a HPLC system consisting of a Waters 590 pump, a Rheodyne 7125 injector, and a Lambda-Max Model 481 LC UV detector (HPLC system II) or a Shimadzu HPLC system (SCL-10A system controller, SIL-10AD autoinjector, LC-10AT pump, CTO-10AC column oven, FRC-10A fraction collector, and SPD-M10A PDA detector; controlled with Shimadzu Class-VP ver. 6.10 software; HPLC system III). HPLC-PDA-MS-SPE-NMR experiments were performed as described in details previously (Sprogøe et al., 2008).

### 4.2. Plant material

Aerial parts of *D. angulifolius* (DC.) H. Rob. & B. Kahn [syn. *V. angulifolia* DC.] (Asteraceae) were collected at an altitude of 665 m in the Botanical Garden of University of KwaZulu-Natal, Pietermaritzburg, on January 5th 2006. The identity of the plant was confirmed by Professor T.J. Edwards and a voucher specimen (Accession Number: Chukwujekwu #1 NU) has been deposited in the Herbarium at the University of KwaZulu-Natal, Pietermaritzburg.



**Table 1**<sup>1</sup>H and <sup>13</sup>C NMR spectroscopic data of **1** and **2**.

Vernangulide A ( <b>1</b> )				Vernangulide B ( <b>2</b> )			
pos.	δ <sub>C</sub> <sup>a</sup>	δ <sub>H</sub> (J in Hz) <sup>a,b</sup>	HMBC <sup>c</sup>	δ <sub>C</sub> <sup>a</sup>	δ <sub>H</sub> (J in Hz) <sup>a,b</sup>	HMBC <sup>c</sup>	
1	135.5	5.74 (ddd, J <sub>1,2A</sub> = 8.2, J <sub>1,2B</sub> = 8.2, J <sub>1,9B</sub> = 1.0)	9, 14	142.4	5.66 (dd, J <sub>1,2B</sub> = 17.8, J <sub>1,2A</sub> = 11.1)	10, 14	
2	25.4	A: 1.92 (br, s) B: 2.70 (br, s)		114.7	A: 5.03 (dd, J <sub>2A,1</sub> = 11.1, J <sub>2A,2B</sub> = 1.0) B: 5.00 (dd, J <sub>2B,1</sub> = 17.8, J <sub>2B,2A</sub> = 1.0)	1, 10 10	
3	24.9	A: 2.78 (ddd, J <sub>3A,3B</sub> = 12.5, J <sub>3A,2A</sub> = 3.5, J <sub>3A,2B</sub> = 3.5) B: 2.30 (ddd, J <sub>3B,3A</sub> = 12.5, J <sub>3B,2A</sub> = 12.5, J <sub>3B,2B</sub> = 4.7, J <sub>3B,5</sub> = 1.0)	1, 2, 4, 5, 15 1, 2, 4, 5, 15	140.4	A: 6.56 (s) B: 6.62 (s)	4, 5, 15	
4	142.3			145.2			
5	148.5	6.54 (dd, J <sub>5,6</sub> = 10.4, J <sub>5,3B</sub> = 1.0)	3, 7, 15	46.7	3.36 (d, J <sub>5,6</sub> = 12.3)	4, 6, 10	
6	76.5	5.38 (dd, J <sub>6,5</sub> = 10.4, J <sub>6,7</sub> = 1.8)	4, 5, 7, 8, 11, 12	77.8	4.91 (dd, J <sub>6,5</sub> = 12.3, J <sub>6,7</sub> = 11.3)		
7	49.6	3.43 (ddd, J <sub>7,8</sub> = 9.8, J <sub>7,6</sub> = 1.8, J <sub>7,13A</sub> = 1.8, J <sub>7,13B</sub> = 1.8)	5, 8, 9, 11, 12, 13	52.1	3.21 (ddd, J <sub>7,6</sub> = 11.3, J <sub>7,8</sub> = 11.0, J <sub>7,13A</sub> = 3.0, J <sub>7,13B</sub> = 3.0)		
8	70.7	5.26 (ddd, J <sub>8,9B</sub> = 12.0, J <sub>8,7</sub> = 9.8, J <sub>8,9A</sub> = 4.0)	6, 16	70.3	5.44 (ddd, J <sub>8,7</sub> = 11.0, J <sub>8,9ax</sub> = 10.7, J <sub>8,9</sub> eq = 4.3)		
9	42.5	A: 2.51 (ddd, J <sub>9A,9B</sub> = 12.0, J <sub>9A,8</sub> = 12.0, J <sub>9A,1</sub> = 1.0) B: 2.81 (dd, J <sub>9B,9A</sub> = 12.0, J <sub>9B,8</sub> = 4.0)	1, 7, 8, 10, 14 1, 7, 8, 10, 14	40.5	ax: 1.86 (dd, J <sub>9ax,9</sub> eq = 13.4, J <sub>9ax,8</sub> = 10.7) eq: 2.44 (dd, J <sub>9</sub> eq,9ax = 13.4, J <sub>9</sub> eq,8 = 4.3)	5, 7, 8	
10	131.8			45.5			
11	135.3			138.0			
12	169.3			168.4			
13	127.9	A: 6.25 (dd, J <sub>13A,7</sub> = 1.8, J <sub>13A,13B</sub> = 1.8) B: 5.87 (dd, J <sub>13B,7</sub> = 1.8, J <sub>13B,13A</sub> = 1.8)	7, 8, 11, 12 7, 8, 11, 12	120.2	A: 6.01 (d, J <sub>13A,7</sub> = 3.0) B: 5.64 (d, J <sub>13B,7</sub> = 3.0)	7	
14	62.6	4.86 (2H, AB spin system)		66.3	A: 4.05 (d, J <sub>14a,14b</sub> = 11.8) B: 4.28 (d, J <sub>14b,14a</sub> = 11.8)	5, 9, 20 1, 9, 20	
15	195.0	9.52 (s)		195.3	9.60 (s)	4, 5	
16	165.5			166.0			
17	141.9			141.7			
18	61.1	4.26 (2H, AB spin system)	16, 17, 19, 8	61.4	4.33 (2H, AB spin system)	17, 19	
19	124.6	A: 5.94 (d, J <sub>19A,19B</sub> = 1.8) B: 6.24 (d, J <sub>19B,19A</sub> = 1.8)	16, 18 16, 18	125.4	A: 5.97 (d, J <sub>19A,19B</sub> = 1.7) B: 6.26 (d, J <sub>19B,19A</sub> = 1.7)	18 16, 18	
20	170.9			171.2			
21	20.8	2.09 (3H, s)	14, 20	21.1	2.09 (3H, s)	20	

<sup>a</sup> <sup>1</sup>H (600 MHz) and <sup>13</sup>C (100 MHz) NMR spectral data measured in acetone-*d*<sub>6</sub>, δ values relative to internal TMS.<sup>b</sup> Multiplicity of signals is given in parentheses: s, singlet; d, doublet; br, broad; coupling constants (apparent splittings) are reported as numerical values in Hz.<sup>c</sup> Signal correlating with <sup>1</sup>H resonance, optimized for η<sub>C,H</sub> = 7.7 Hz.

### 4.3. Extraction and sample preparation

Aerial parts (395 g) were successively extracted with dichloromethane/methanol 1:1 (2 × 2 l) and methanol (2 × 2 l) overnight at room temperature. The combined extracts were concentrated *in vacuo*, and freeze dried to give 67 g of raw extract. The extract was defatted by redissolving in 1 l of methanol–water (9:1) and extracting with petroleum ether (20 × 0.5 l, b.p. 80–100 °C), which yielded 56 g of defatted extract. Leaves (350 g) were sonication for 1 h with 1 l acetone and then left for extraction overnight. Extraction was subsequently repeated three times with 0.5 l acetone, and the combined extracts were evaporated under reduced pressure at 30 °C to give 19 g of extract.

### 4.4. HPLC–PDA–MS–SPE–NMR analysis

Separation of defatted extract was performed at 40 °C on a 150 × 4.6 mm i.d. Phenomenex C<sub>18</sub>(2) Luna column (3 μm, 100 Å) with a flow rate of 0.8 ml/min using a mixture of water–acetonitrile

95:5 + 0.1% formic acid (eluent A) and acetonitrile–water 95:5 + 0.1% formic acid (eluent B). Five repeated separations (30 μl injection volume, 100 mg/ml, gradient profile: 0 min, 18% B; 13 min, 18% B; 28 min, 32% B; 43 min 32% B; 53 min, 100% B; 60 min, 100% B; 62 min, 18% B; 72 min 18% B) were performed using UV threshold-based trapping (220 and 254 nm) of analytes on GP phase SPE cartridges (general-purpose poly(divinylbenzene)-based resin from Spark Holland, 10 × 2 mm i.d.; water post-column dilution, 2 ml/min).

### 4.5. Preparative-scale isolation

Initial separation of defatted extract was performed with HPLC system I on a 250 × 21.2 mm i.d. Phenomenex C<sub>18</sub>(2) Luna column (5 μm, 100 Å) with a flow rate of 20 ml/min. Mixtures of water–acetonitrile 95:5 + 0.1% TFA (eluent A) and acetonitrile–water 95:5 + 0.1% TFA (eluent B) were used for separation of 3.1 g (900 μl pr. injection, 250 mg/ml solution) using the following gradient profile: 0 min, 25% B; 5 min, 25% B; 20 min, 32% B; 33 min,

**Table 2**Antiplasmodial and cytotoxic activity of **1–4** against *P. falciparum* D10 and W2 strains and Chinese hamster ovarian cell line.

Compounds	IC <sub>50</sub> (μM)			Resistance index <sup>b</sup>	Selectivity index <sup>c</sup>
	D10 (n = 2) <sup>a</sup>	W2 (n = 2)	CHO (n = 3)		
<b>1</b>	1.90 ± 0.10	3.24 ± 0.27	3.52 ± 1.63	1.7	1.9
<b>2</b>	1.55 ± 0.02	2.10 ± 0.17	8.28 ± 0.39	1.4	5.3
<b>3</b>	3.82 ± 0.08	4.94 ± 0.18	26.38 ± 1.85	1.3	6.9
<b>4</b>	1.75 ± 0.35	2.69 ± 0.26	4.47 ± 0.64	1.5	2.6
Chloroquine	0.04 ± 0.004	0.16 ± 0.055			
Emetine			0.09 ± 0.04		

<sup>a</sup> n = number of replicates.<sup>b</sup> Resistance index = IC<sub>50</sub> W2/IC<sub>50</sub> D10.<sup>c</sup> Selectivity index = IC<sub>50</sub> CHO/IC<sub>50</sub> D10.

32% B; 38 min, 100% B; 43 min, 100% B; 45 min, 25% B; 55 min, 25% B. Manual collection based on absorption levels at 220 and 254 nm afforded seven fractions (A–G) and  $^1\text{H}$  NMR spectra of the fractions showed that only fraction A (34 mg) and fraction C (112 mg) contained sesquiterpene lactones. HPLC system II and the above-mentioned HPLC column were used to rechromatograph fraction A and C. Thus, isocratic elution of fraction A (water–acetonitrile–formic acid 80:20:0.1) yielded 3.2 mg of (**3**) whereas isocratic elution of fraction C (water–acetonitrile–formic acid 65:35:0.1) yielded fractions C1–C5. Fraction C4 (2 mg, norartocarpetin and luteolin, 2:1 mixture) was not further purified, but fraction C2 (13 mg) and C5 (52 mg) were rechromatographed on HPLC system III using the same HPLC column and eluents as for the HPLC–PDA–MS–SPE–NMR analysis. Isocratic separation of 7.7 mg of fraction C2 (water–acetonitrile–formic acid 82:18:0.1) yielded 2.7 mg of 2:1 mixture of **6** and **7**, whereas isocratic separation of 13.6 mg of fraction C5 (water–acetonitrile–formic acid 80:20:0.1) yielded 1.3 mg of **4** and 3.0 mg of **5**.

#### 4.6. Bioassay-guided isolation

Column chromatography (Merck 9385, 200 g,  $2.5 \times 73$  cm) of the acetone extract, using hexane–acetone step gradients (10:0, 9:1, 4:1, 7:3, 3:2, 1:1, 2:3, 3:7, 1:4, and 0:10; 0.5 l each), yielded 355 fractions which were pooled into 16 fractions based on similarity of TLC profiles using UV light at 254 and 365 nm for visualization. All fractions were assessed for antiparasmodial activity against chloroquine sensitive D10 *P. falciparum* strain at concentrations of 5, 2.5, and 1.25  $\mu\text{g}/\text{ml}$ . Fractions 11 (1.197 g) and 12 (5.6 g) eluted with hexane–acetone (7:3 and 3:2, respectively), were found to be the most active. Repeated purification of the two fractions by column chromatography (Merck 9385, 120 g,  $2.5 \times 73$  cm), using hexane–EtOAc step gradients (same as above), produced 200 and 230 fractions, respectively. Fractions were again pooled based on similar TLC profiles to give 17 (Fr<sub>11</sub>S1–Fr<sub>11</sub>S17) and 15 (Fr<sub>12</sub>S1–Fr<sub>12</sub>S15) subfractions, respectively, which were subjected to antiparasmodial bioassay. A final purification of constituents from the active fractions were performed by preparative TLC using a hexane–EtOAc (3:1) solvent system, and this yielded 14.5 mg of **1**, 1 mg of **2**, 13 mg of **3**, and 59 mg of a mixture of **4** and **5**.

#### 4.7. Antiparasmodial assay

Continuous *in vitro* cultures of asexual erythrocyte stages of chloroquine sensitive D10 strain and chloroquine resistant W2 strain of *P. falciparum* were maintained using a modified method of Trager and Jensen (1976), and quantitative assessment of antiparasmodial activity *in vitro* was determined via the parasite lactate dehydrogenase assay (Makler et al., 1993) as described in details elsewhere (Clarkson et al., 2003; Pillay et al., 2007).

#### 4.8. Cytotoxicity assay

Quantitative assessment of cytotoxicity was assessed with an *in vitro* assay (Mosmann, 1983; Rubinstein et al., 1990) using the Chinese Hamster Ovarian cell line as described previously (Clarkson et al., 2003; Pillay et al., 2007).

#### 4.9. Compound 1

*Vernangulide A* [(6S,7R,8S)-14-acetoxy-8-[2-hydroxymethylacrylat]-15-helianga-1(10),4,11(13)-trien-15-al-6,12-olid] (**1**):  $[\alpha]_{\text{D}}^{20} = -9.2$  (c 0.68,  $\text{CHCl}_3$ );  $^1\text{H}$  and  $^{13}\text{C}$  NMR data see Table 1; HREIMS  $m/z$  427.1369  $[\text{M}+\text{Na}]^+$  (calc. for  $[\text{C}_{21}\text{H}_{24}\text{O}_8\text{Na}]^+$ , 427.1363).

#### 4.10. Compound 2

*Vernangulide B* [(5R,6R,7R,8S,10S)-14-acetoxy-8-[2-hydroxymethylacrylat]-elema-1,3,11(13)-trien-15-al-6,12-olid] (**2**):  $[\alpha]_{\text{D}}^{20} = +26.3$  (c 17,  $\text{CHCl}_3$ ),  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR data see Table 1; HREIMS  $m/z$  427.1442  $[\text{M}+\text{Na}]^+$  (calc. for  $[\text{C}_{21}\text{H}_{24}\text{O}_8\text{Na}]^+$ , 427.1363).

#### Acknowledgement

NMR equipment used in this work was purchased via a grant from “Apotekerfonden af 1991” (Copenhagen). Ms. Birgitte Simonson (Department of Medicinal Chemistry, University of Copenhagen) is acknowledged for technical assistance. The National Research Foundation, Pretoria and the University of KwaZulu-Natal are thanked for financial assistance.

#### Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.phytochem.2009.02.005.

#### References

- Abegaz, B.M., Keige, A.W., Díaz, J.D., Herz, W., 1994. Sesquiterpene lactones and other constituents of *Vernonia* species from Ethiopia. *Phytochemistry* 37, 191–196.
- Al Magboul, A.Z.I., Bashir, A.K., Khalid, S.A., Farouk, A., 1997. Antimicrobial activity of vernolepin and vernodaline. *Fitoterapia* 68, 83–84.
- Biagini, C.A., Ward, S.A., Bray, P.G., 2005. Malaria parasite transporters as a drug-delivery strategy. *Trends Parasitol.* 21, 299–301.
- Bohlmann, F., Brindöpke, G., Rastogi, C., 1978. A new type of germacranolide from *Vernonia* species. *Phytochemistry* 17, 475–482.
- Bourdy, G., Willcox, M.L., Ginsburg, H., Rasoaivo, P., Graz, B., Deharo, E., 2008. Ethnopharmacology and malaria: new hypothetical leads or old efficient antimalarials? *Int. J. Parasitol.* 38, 33–41.
- Butler, M.S., 2004. The role of natural products chemistry in drug discovery. *J. Nat. Prod.* 67, 2141–2153.
- Cardona, L., García, B., Muñoz, M.C., Navarro, F.I., Pedro, J.R., 1997. New sesquiterpene lactones and other constituents from *Centaurea paui*. *Liebigs Ann.* 3, 527–532.
- Cioffi, G., Sanogo, R., Diallo, D., Romussi, G., De Tommasi, N., 2004. New compounds from an extract of *Vernonia colorata* leaves with anti-inflammatory activity. *J. Nat. Prod.* 67, 389–394.
- Clarkson, C., Campbell, W.E., Smith, P., 2003. *In vitro* antiparasmodial activity of abietane and totarane diterpenes isolated from *Harpagophytum procumbens* (Devil's claw). *Planta Med.* 69, 720–724.
- Clarkson, C., Stærk, D., Hansen, S.H., Smith, P.J., Jaroszewski, J.W., 2006a. Discovering new natural products directly from crude extracts by HPLC–SPE–NMR: chinane diterpenes in *Harpagophytum procumbens*. *J. Nat. Prod.* 69, 527–530.
- Clarkson, C., Stærk, D., Hansen, S.H., Smith, P.J., Jaroszewski, J.W., 2006b. Identification of major and minor constituents of *Harpagophytum procumbens* (Devil's Claw) using HPLC–SPE–NMR and HPLC–ESIMS/APCIMS. *J. Nat. Prod.* 69, 1280–1288.
- Cuenca, M.R., Borkosy, S., Catalán, C.A.N., Goedken, V.L., Díaz, J.G., Herz, W., 1993. Sesquiterpene lactones of *Mikania minima*. *Phytochemistry* 32, 1509–1513.
- Erasto, P., Grierson, D.S., Afolayan, A.J., 2006. Bioactive sesquiterpene lactones from the leaves of *Vernonia amygdalina*. *J. Ethnopharmacol.* 106, 117–120.
- Erasto, P., Grierson, D.S., Afolayan, A.J., 2007. Antioxidant constituents in *Vernonia amygdalina* leaves. *Pharm. Biol.* 45, 195–199.
- Fortuna, A.M., de Riscala, E.C., Catalan, C.A.N., Gedris, T.E., Herz, W., 2001. Sesquiterpene lactones from *Centaurea tweediei*. *Biochem. Syst. Ecol.* 29, 967–971.
- Ganjan, I., Kubo, I., Fludzinski, P., 1983. Insect antifeedant eleanolide lactones from *Vernonia amygdalina*. *Phytochemistry* 22, 2525–2526.
- Huffman, M.A., Seifu, M., 1989. Observations on the illness and consumption of a possibly medicinal plant *Vernonia amygdalina* (DEE.), by a wild chimpanzee in the Mahale Mountains National Park, Tanzania. *Primates* 30, 51–63.
- Jakupovic, J., Zdero, C., Boeker, R., Warning, U., Bohlmann, F., Jones, S.B., 1987. Vernocistifolide und andere sesquiterpenelactone aus *Vernonia* und verwandten arten. *Liebigs Ann.* 1987, 111–123.
- Jisaka, M., Kawanaka, M., Sugiyama, H., Takegawa, K., Huffman, M.A., Ohgashi, H., Koshimizu, K., 1992. Antischistosomal activities of sesquiterpene lactones and steroid glucosides from *Vernonia amygdalina*, possibly used by wild chimpanzees against parasite-related diseases. *Biosci. Biotech. Biochem.* 56, 845–846.
- Jisaka, M., Ohgashi, H., Takegawa, K., Huffman, M.A., Koshimizu, K., 1993. Antitumoral and antimicrobial activities of bitter sesquiterpene lactones of

- Vernonia amygdalina*, a possible medicinal plant used by wild chimpanzees. Biosci. Biotech. Biochem. 57, 833–834.
- Karamenderes, C., Bedir, E., Pawar, R., Baykan, S., Khan, I.A., 2007. Elemanolide sesquiterpenes and eudesmane sesquiterpene glycosides from *Centaurea hierapolitana*. Phytochemistry 68, 609–615.
- Koshimizu, K., Ohigashi, H., Huffman, M.A., 1994. Use of *Vernonia amygdalina* by wild chimpanzee: possible roles of its bitter and related constituents. Physiol. Behav. 56, 1209–1216.
- Koul, J.L., Koul, S., Singh, C., Taneja, S.C., Shanmugavel, M., Kampasi, H., Saxena, A.K., Qazi, G.N., 2003. *In vitro* cytotoxic elemanolides from *Vernonia lasiopus*. Planta Med. 69, 164–166.
- Makler, M.T., Ries, J.M., Williams, J.A., Bancroft, J.E., Piper, R.C., Gibbins, B.L., Hinrichs, D., 1993. Parasite lactate dehydrogenase as an assay for *Plasmodium falciparum* drug sensitivity. J. Am. Soc. Trop. Med. Hygiene 48, 739–741.
- Mosmann, T., 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immun. Methods 65, 55–63.
- Ohigashi, H., Huffman, M.A., Izutsu, D., Koshimizu, K., Kawanaka, M., Sugiyama, H., Kirby, G.C., Warhurst, D.C., Allen, D., Wright, C.W., Phillipson, J.D., Timon-David, P., Delmas, F., Elias, R., Balansard, G., 1994. Toward the chemical ecology of medicinal plant use in chimpanzees: the case of *Vernonia amygdalina*, a plant used by wild chimpanzees possibly for parasite-related diseases. J. Chem. Ecol. 20, 541–553.
- Pillay, P., Vleggaar, R., Maharaj, V.J., Smith, P.J., Lategan, C.A., 2007. Isolation and identification of antiplasmodial sesquiterpene lactones from *Oncosiphon piluliferum*. J. Ethnopharmacol. 112, 71–76.
- Pooley, E., 1998. A Field Guide to Wild Flowers: Kwazulu-Natal and the East Region. Natal Flora Publications Trust, Durban.
- Pukalskas, A., van Beek, T.A., de Ward, P., 2005. Development of a triple hyphenated HPLC-radical scavenging detection-DAD-SPE-NMR system for the rapid identification of antioxidants in complex plant extracts. J. Chromatogr. A 1074, 81–88.
- Rabe, T., Mullholland, D., van Staden, J., 2002. Isolation and identification of antibacterial compounds from *Vernonia colorata* leaves. J. Ethnopharmacol. 80, 91–94.
- Reid, K.A., Jäger, A.K., van Staden, J., 2001. Isolation of the anti-bacterial vernodaline from traditionally used *Vernonia colorata*. S. Afr. J. Bot. 67, 71–73.
- Robinson, H., 2006. Vernonieae. In: Kadereit, J.W., Jeffrey, C. (Eds.), The Families and Genera of Vascular Plants, Flowering Plants. Eudicots. Asterales, vol. 8. Springer, Berlin, pp. 149–174.
- Robinson, H., Kahn, B., 1986. Trinervate leaves, yellow flowers, tailed anthers, and pollen variation in *Distephanus* Cassini (*Vernonieae*, *Asteraceae*). Proc. Biol. Soc. Wash. 99, 493–501.
- Roselli, S., Maggio, A., Raccuglia, R.A., Bruno, M., 2003. Rearrangement of germacranolides. Synthesis and absolute configuration of elemene and heliangolane derivatives from cnicin. Eur. J. Org. Chem., 2690–2694.
- Rubinstein, L.V., Shoemaker, R.H., Paull, K.D., Simon, R.M., Tosini, S., Skehan, P., Scudiero, D.A., Monks, A., Boyd, M.R., 1990. Comparison of *in vitro* anticancer-drug-screening data generated with a tetrazolium assay against a diverse panel of human tumor cell lines. J. Natl. Cancer Inst. 82, 1113–1118.
- Sairafianpour, M., Bahreininejad, B., Witt, M., Ziegler, H.L., Jaroszewski, J.W., Stærk, D., 2003. Terpenoids of *Salvia hydrangea*: two new, rearranged 20-norabietanes and the effect of oleanolic acid on erythrocyte membrane. Planta Med. 69, 846–850.
- Schmidt, B., Jaroszewski, J.W., Bro, R., Witt, M., Stærk, D., 2008. Combining PARAFAC analysis of HPLC-PDA profiles and structural characterization using HPLC-PDA-SPE-NMR-MS experiments: commercial preparations of St. John's wort. Anal. Chem. 80, 1978–1987.
- Scotti, M.T., Fernandes, M.B., Ferreira, M.J.P., Emerenciano, V.P., 2007. Quantitative structure-activity relationship of sesquiterpene lactones with cytotoxic activity. Bioorg. Med. Chem. 15, 2927–2934.
- Seaman, F.C., Fischer, N.H., 1980. Six new melampolides from *Tetragonotheca heliantholides*. Phytochemistry 19, 583–586.
- Sørensen, D., Raditsis, A., Trimble, L.A., Blackwell, B.A., Sumarah, M.W., Miller, J.D., 2007. Isolation and structure elucidation by LC-MS-SPE/NMR: PR toxin- and cuspidatol-related eremophilane sesquiterpenes from *Penicillium roqueforti*. J. Nat. Prod. 70, 121–123.
- Sprogø, K., Jäger, A.K., Adersen, A., Hansen, S.H., Witt, M., Landbo, A.-K.R., Meyer, A.S., Jaroszewski, J.W., 2007. Targeted natural product isolation guided by HPLC-SPE-NMR: constituents of *Hubertia* species. J. Nat. Prod. 70, 1472–1477.
- Sprogø, K., Stærk, D., Ziegler, H.L., Jensen, T.H., Holm-Møller, S.B., Jaroszewski, J.W., 2008. Combining HPLC-PDA-MS-SPE-NMR with circular dichroism for complete natural product characterization in crude extracts: levorotatory gossypol in *Thespesia danis*. J. Nat. Prod. 71, 516–519.
- Tatsis, E.C., Boeren, S., Exarchou, V., Troganis, A.N., Vervoort, J., Gerothanassis, I.P., 2007. Identification of the major constituents of *Hypericum perforatum* by LC/SPE/NMR and/or LC/MS. Phytochemistry 68, 383–393.
- Trager, W., Jensen, J.B., 1976. Human malaria parasite in continuous culture. Science 193, 673–675.
- Zhang, S., Won, Y.-K., Ong, C.-N., Shen, H.-M., 2005. Anti-cancer potential of sesquiterpene lactones: bioactivity and molecular mechanisms. Curr. Med. Chem. 5, 239–249.
- Ziegler, H.L., Stærk, D., Christensen, J., Hviid, L., Hägerstrand, H., Jaroszewski, J.W., 2002. Artefacts in the *in vitro* *Plasmodium falciparum* growth inhibition assay caused by stomatocytogenic amphiphiles. Antimicrob. Agents Chemother. 64, 1441–1446.
- Ziegler, H.L., Franzyk, H., Sairafianpour, M., Tabatabai, M., Tehrani, M.D., Bagherzadeh, K., Hägerstrand, H., Stærk, D., Jaroszewski, J.W., 2004. Erythrocyte membrane modifying agents and the inhibition of *Plasmodium falciparum* growth: structure-activity relationships for betulinic acid analogues. Bioorg. Med. Chem. 12, 119–127.